On this page Jump to a section
- Key facts
- Does Ozempic cause erectile dysfunction?
- What each GLP-1 label lists
- What studies in men show
- What the newest studies say (October 2026)
- Can you take Viagra or Cialis with Ozempic?
- What each path includes
- What to bring to your prescriber or ED visit
- Safety checks before ED medication
- If ED is the problem you want treated now
- Mendoxa plans and prices
- FAQ
- How we wrote this
- Sources and references
Key facts at a glance
- Label wording
- Ozempic does not list erectile dysfunction, impotence or decreased libido; absence from a label does not rule out a possible effectOzempic (semaglutide) label · DailyMed
- Study signal
- ED diagnosis or PDE5 prescription: 1.47% with semaglutide vs 0.32% without it in matched men without diabetes (association only) Ozempic (semaglutide) labelAble et al. 2025 · PubMed
- Tirzepatide
- Zepbound does not list ED or decreased libido; see the label table for blood pressure findingsZepbound (tirzepatide) label · DailyMed
- With sildenafil
- No GLP-1 interaction listed; nitrates are contraindicatedViagra (sildenafil) label · DailyMed
- Compounded status
- The Mendoxa compounded tablet is not FDA-approvedFDA compounding Q&A
Does Ozempic cause erectile dysfunction?
A symptom starting after a prescription deserves review, even when it is absent from the label. The Ozempic (semaglutide) label does not list ED; the semaglutide database study below found more ED diagnoses or PDE5 prescriptions in one selected group of men. Neither finding settles what caused your symptoms.
NIDDK lists diabetes, obesity, blood vessel disease and low testosterone among conditions that can lead to ED. An assessment can consider these alongside your medication history.
If diabetes is part of your history, read ED and diabetes; if desire dropped too, see low testosterone and ED.
What each GLP-1 label lists
We searched the full text of each U.S. label rather than relying on summaries. The answer is the same across semaglutide and tirzepatide products: no erectile dysfunction, impotence or libido entry.
| U.S. label (revised) | Erectile dysfunction, impotence or libido | Most common reactions (≥5%) | Blood pressure and fluid wording |
|---|---|---|---|
| Ozempic, semaglutide (5/2026) | Not listed: no entry for erectile dysfunction, impotence, libido or sexual function | “nausea, vomiting, diarrhea, abdominal pain and constipation” (Ozempic (semaglutide) label) | No hypotension entry; warns of acute kidney injury mostly in patients with “gastrointestinal reactions leading to dehydration” (Ozempic (semaglutide) label) |
| Wegovy, semaglutide (6/2026) | Not listed | Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dizziness and others (Wegovy (semaglutide) label) | Hypotension-related reactions in 1.3% of adults vs 0.4% on placebo; “more frequently seen in patients on concomitant antihypertensive therapy” (Wegovy (semaglutide) label) |
| Mounjaro, tirzepatide (8/2026) | Not listed | “nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain” (Mounjaro (tirzepatide) label) | No hypotension entry; same dehydration and kidney warning (Mounjaro (tirzepatide) label) |
| Zepbound, tirzepatide (8/2026) | Not listed | Nausea, diarrhea, vomiting, constipation, abdominal pain, fatigue, hair loss and others (Zepbound (tirzepatide) label) | Hypotension 1.6% vs 0.1% on placebo; it “also occurred in association with gastrointestinal adverse events and dehydration” (Zepbound (tirzepatide) label) |
Sources: Ozempic (semaglutide) label, Novo Nordisk, 5/2026; Wegovy (semaglutide) label, Novo Nordisk, 6/2026; Mounjaro (tirzepatide) label, Eli Lilly, 8/2026; Zepbound (tirzepatide) label, Eli Lilly, 8/2026. Full label text searched for “erectile”, “impotence”, “libido” and “sexual”. Accessed Oct 26, 2026.
“Not listed” means the terms were absent from the label text we checked; it does not mean zero risk. The Wegovy (semaglutide) label and Zepbound (tirzepatide) label report hypotension in their clinical trials; these figures come from separate trials and should not be used to rank the drugs against each other.
Semaglutide, tirzepatide and ED: what studies in men show
The research points in both directions, and none of it proves cause. The two database studies in this table are observational; the randomized trial tested lifestyle weight loss. The newer pooled evidence appears in the next section.
| Study | Who was studied | Finding | What it cannot tell you |
|---|---|---|---|
| Able et al., Int J Impot Res 2025 (semaglutide label) | 3,094 men aged 18–50 without diabetes, BMI over 30, prescribed semaglutide, vs matched men who were not | New ED diagnosis or PDE5 prescription: 1.47% vs 0.32% (risk ratio 4.5) | Database association; it does not show that semaglutide caused ED |
| Cowart et al., J Diabetes Complications 2025 (tirzepatide label) | Men aged 18–70 with type 2 diabetes and no prior ED | ED diagnosis or PDE5 prescription: risk ratios of 0.70 vs sitagliptin, 0.67 vs injectable semaglutide and 0.55 vs dulaglutide | Observational; the authors call for randomized trials |
| Esposito et al., JAMA 2004 (diet and exercise, no GLP-1) | 110 men with obesity and ED, without diabetes | Erectile function score rose from 13.9 to 17 over 2 years with weight loss, vs 13.5 to 13.6 in controls | Lifestyle weight loss, not a GLP-1 medicine |
Sources: PubMed 38778151; PubMed 40614622; PubMed 15213209; labels: Ozempic (semaglutide) label, Mounjaro (tirzepatide) label. Accessed Oct 26, 2026.
Read the outcome before the headline. The semaglutide study counted a new ED diagnosis or a PDE5 prescription, not only confirmed diagnoses, and its findings in men without diabetes do not automatically apply to every GLP-1 user (Able et al.; Ozempic (semaglutide) label). The lifestyle trial supports diet and exercise as a separate line of evidence; it does not establish an ED benefit for semaglutide.
What the newest studies say (October 2026)
Two 2026 meta-analyses point the other way from the 2025 database study: in men with obesity or type 2 diabetes, GLP-1 drugs were linked with better erections and higher testosterone. Both pooled small studies, so they show an association, not proof, and neither makes Ozempic an ED treatment. The Ozempic (semaglutide) label and Wegovy (semaglutide) label do not list erectile dysfunction as an indication.
| Study | Design | Men | Finding | Limitation |
|---|---|---|---|---|
| Corona, Maggi et al., Andrology 2026 | Systematic review and meta-analysis of observational studies and randomized trials (Medline to August 2025) | 8 GLP-1 studies, 375 participants with overweight or obesity, with or without diabetes | Improved erectile function outcomes; higher total and calculated free testosterone; the testosterone association was independent of observed weight loss; testosterone therapy did better than GLP-1s on orgasm and sexual satisfaction | Small pooled sample; mixes observational studies and trials |
| Lima et al., J Sex Med 2026 (conference abstract) | Systematic review and meta-analysis of randomized trials and observational studies (to July 2025) | 6 studies, 470 men with type 2 diabetes or obesity and ED | IIEF sexual-function score improved (SMD 1.28; 95% CI 0.39–2.18); total testosterone rose modestly; free testosterone and SHBG changes were not significant | Substantial heterogeneity; study quality mostly “fair”; abstract only; authors call for more RCTs |
Sources: Corona G, et al. Andrology 2026;14(7):1988-2001, doi:10.1111/andr.70238 (abstract); Lima JPC, et al. J Sex Med 2026;23(Suppl 4), doi:10.1093/jsxmed/qdag118.035 (abstract). Figures as reported in each abstract; SMD = standardized mean difference, not IIEF points or a percentage of men helped. Label boundary: Ozempic (semaglutide) label; Wegovy (semaglutide) label. Accessed Oct 26, 2026.
What this means for you: the 2026 meta-analyses and the 2025 database study looked at different men and different outcomes, so neither settles the question. The J Sex Med abstract calls for further randomized trials; the Ozempic (semaglutide) label still does not list ED, testosterone or libido effects. If erections are the problem now, ED treatment is assessed separately from your GLP-1, and the online visit is one way to start.
Keep the outcomes separate: an erection score, a testosterone blood test and interest in sex answer different questions. Tell the provider which change you noticed rather than assuming one explains the others.
Can you take Viagra or Cialis with Ozempic?
Taking a GLP-1 does not replace the need for an individual ED medication review. Neither the Viagra (sildenafil) label nor Cialis (tadalafil) label names semaglutide, tirzepatide or GLP-1 in its interaction text; that absence is not clearance to combine medicines.
Blood pressure is the overlap to discuss. The Viagra (sildenafil) label advises caution with anti-hypertensives because combined use may lead to hypotension, and the Cialis (tadalafil) label gives a similar warning. On the GLP-1 side, the Wegovy (semaglutide) label and Zepbound (tirzepatide) label report hypotension more often than placebo, especially with blood pressure medicine or dehydration.
The Ozempic (semaglutide) label and Mounjaro (tirzepatide) label say these drugs delay gastric emptying and may affect absorption of oral medicines; they do not name ED tablets. Sildenafil and tadalafil are contraindicated with nitrates (Viagra (sildenafil) label; Cialis (tadalafil) label). Read ED and blood pressure and ED medication and nitrates.
Could Mendoxa ED care fit you?
Online ED visit · Prescription required · Independent licensed providers · Not available in California
What each path includes
Choose the visit around the question you need answered. Ask your GLP-1 prescriber about a change that began during treatment; use an ED assessment to discuss erection difficulties and whether a prescription is suitable. Bring the same medication list to both.
| Path | Question it addresses | What it includes | Boundary |
|---|---|---|---|
| GLP-1 prescriber review | Erections or desire changed after starting treatment? | Timeline of the GLP-1 and its side effects such as nausea, vomiting or dizziness (Ozempic (semaglutide) label; Zepbound (tirzepatide) label) | Discuss any change to the GLP-1 with the clinician who prescribes it |
| ED assessment | ED predates treatment or keeps recurring? | Medical, sexual and mental health history, exam and tests, including medicines (NIDDK) | Diabetes, obesity, heart disease and low testosterone are common causes (NIDDK) |
| Standalone ED prescription | Want to discuss an ED prescription? | Review of blood pressure, heart health and every medicine (Viagra (sildenafil) label; Cialis (tadalafil) label) | No GLP-1 interaction is listed, which is not a safety clearance |
| Mendoxa 3-in-1 visit | Want an online suitability review? | Online intake that asks about your current medicines; Independent licensed providers review it; Prescription required | Compounded drugs are not FDA-approved |
Sources: Ozempic (semaglutide) label; Zepbound (tirzepatide) label; NIDDK diagnosis; NIDDK causes; Viagra (sildenafil) label; Cialis (tadalafil) label; FDA compounding Q&A; Mendoxa ED care information. Accessed Oct 26, 2026.
Compare ED medication options and the broader erectile dysfunction guide before the visit.
Looking for weight-loss care instead? See the Mendoxa weight-loss program; compounded GLP-1s are not FDA-approved.
What to bring to your prescriber or ED visit
Do not stop or change a GLP-1 on your own because of ED. Ask the clinician who prescribes it; the Ozempic (semaglutide) label and Zepbound (tirzepatide) label describe side effects such as nausea, vomiting and dehydration that are worth reporting too.
Prepare a short note with the medicine name, start date, prescription changes, symptom timeline, and every other medicine or supplement. Include nausea, vomiting or dizziness if present (Ozempic (semaglutide) label; Zepbound (tirzepatide) label); NIDDK’s ED assessment guidance explains why medication and sexual histories matter.
Useful questions: “Could the GLP-1, the weight change or an underlying condition explain this?” and “Would an ED prescription fit my health history?” Read can ED be reversed? for questions about underlying causes.
Safety checks before ED medication
If you use medicine for GLP-1 nausea, name it in your intake. The APOKYN (apomorphine) label contraindicates apomorphine with 5HT3 antagonists such as ondansetron because profound low blood pressure and loss of consciousness have been reported; Mendoxa’s compounded tablet contains apomorphine. This check is separate from the interaction review for sildenafil or tadalafil (Viagra (sildenafil) label; Cialis (tadalafil) label).
- Sildenafil and tadalafil are contraindicated with organic nitrates or riociguat (Viagra (sildenafil) label; Cialis (tadalafil) label).
- An erection lasting more than 4 hours needs immediate medical care (Viagra (sildenafil) label; Cialis (tadalafil) label).
- Stop and seek care for sudden vision loss or sudden decrease or loss of hearing (Viagra (sildenafil) label; Cialis (tadalafil) label).
- Common adverse effects include headache and flushing with sildenafil, and headache, indigestion and back pain with tadalafil (Viagra (sildenafil) label; Cialis (tadalafil) label).
Do not add another ED medicine to an existing treatment on your own: the Viagra (sildenafil) label and Cialis (tadalafil) label say combinations with other PDE5 inhibitors or ED therapies have not been studied and advise against such use.
If ED is the problem you want treated now
Start the online visit to find out whether Mendoxa ED care is appropriate for you. Share your symptoms, health history and current medicines, including your GLP-1. Independent licensed providers assess suitability. Prescription required.
The tablet combines sildenafil, tadalafil and apomorphine; it is not FDA-approved. Ingredient references are the Viagra (sildenafil) label, Cialis (tadalafil) label and APOKYN (apomorphine) label; APOKYN is an injectable Parkinson’s treatment, and its label is not approval of this ED combination.
Use the visit to ask about suitability before choosing a quantity. For background, read about the compounded combination ED tablet and ED medication options.
Mendoxa ED plans and prices
Choose a quantity after the provider assesses suitability. Prescription required · Independent licensed providers. Mendoxa’s compounded tablet is not FDA-approved.
| Tablets per month | 1-month total | Per tablet (1 month) | 3-month total | Per tablet (3 months) |
|---|---|---|---|---|
| 6 tablets / month | $129 | $21.50 | $329 | $18.28 |
| 10 tablets / month | $149 | $14.90 | $379 | $12.63 |
| 20 tablets / month | $179 | $8.95 | $449 | $7.48 |
The 3-month total covers three months at the monthly tablet quantity shown.
If prescribed · Cancel anytime · Available in 49 states (not California). Source: Mendoxa intake pricing supplied for this update; accessed Oct 26, 2026. The intake always shows the current price.
FAQ
Does Ozempic cause impotence in men?
Impotence is not listed in the Ozempic (semaglutide) label or Wegovy (semaglutide) label. A 2025 database study found more new ED diagnoses or PDE5 prescriptions in men without diabetes prescribed semaglutide, but it shows an association, not cause; obesity and diabetes are themselves common ED causes (NIDDK).
Does Mounjaro cause erectile dysfunction?
The Mounjaro (tirzepatide) label and Zepbound (tirzepatide) label do not list erectile dysfunction or libido changes. In a 2025 study of men with type 2 diabetes, tirzepatide was associated with lower ED risk than sitagliptin, semaglutide or dulaglutide; the authors say randomized trials are needed.
Can you take Viagra with Ozempic?
The Viagra (sildenafil) label and Cialis (tadalafil) label list no GLP-1 interaction, but both warn that use with blood pressure medicines may lead to hypotension. The Wegovy (semaglutide) label reports more hypotension than placebo, so a provider should review your blood pressure and every medicine first.
Does Ozempic affect sex drive?
Decreased libido is not listed in the Ozempic (semaglutide) label. That does not rule out an individual change. Describe whether you mean less desire, trouble getting or keeping an erection, or both. For recurring erection difficulties, why you cannot stay hard can help you prepare for the visit.
Can weight loss pills cause erectile dysfunction?
Yes, some can: the phentermine hydrochloride label lists impotence and changes in libido. Evidence about semaglutide cannot answer for every weight-loss pill. The Ozempic (semaglutide) label and Wegovy (semaglutide) label do not list ED as an indication or adverse reaction. Bring the product name and symptom timeline to your prescriber, and ask for a separate ED assessment if erections remain a concern.
Does Ozempic help ED or raise testosterone?
It is not an ED treatment: the Ozempic (semaglutide) label and Wegovy (semaglutide) label do not list ED as an indication. Two 2026 meta-analyses pooling small studies of 375 and 470 men (Corona et al.; Lima et al.) linked GLP-1 drugs with better erectile function scores and higher total testosterone in men with obesity or type 2 diabetes; these pooled findings do not prove an individual benefit, and the J Sex Med abstract calls for further randomized trials.
Will losing weight on a GLP-1 improve my erections?
It may for some men, but it cannot be promised. A JAMA trial of lifestyle weight loss improved erectile function in about one third of men with obesity; no GLP-1 label lists ED as an indication (Ozempic (semaglutide) label; Zepbound (tirzepatide) label).
Can I get ED treatment online while taking a GLP-1?
Yes, you can start an online visit and disclose your GLP-1 and all other medicines; prescribing depends on the provider’s review, including the precautions in the Viagra (sildenafil) label and Cialis (tadalafil) label. Independent licensed providers assess suitability. Prescription required. Mendoxa’s compounded tablet is not FDA-approved; the ingredient labels do not establish the safety or effectiveness of that combination.
Ready to see if the Mendoxa ED tablet fits you?
From $129/month if prescribed · Cancel anytime · Available in 49 states (not California)
How we wrote this
Written by the Mendoxa editorial team · Sources: DailyMed/FDA, PubMed and NIH (NIDDK). We checked labels and study abstracts on Oct 26, 2026. The Ozempic (semaglutide) label and Wegovy (semaglutide) label do not establish an ED indication. We distinguish database associations, pooled studies and a lifestyle randomized trial; none predicts your individual response. Ingredient labels describe their approved products and do not establish the safety or effectiveness of Mendoxa’s compounded combination.
Updated Oct 26, 2026. This page is general information. A licensed clinician decides what fits you.
References
- DailyMed: phentermine hydrochloride tablets, adverse reactions. Accessed Oct 26, 2026.
- DailyMed: VIAGRA (sildenafil citrate) tablet, film coated, label revised 12/2017. Accessed Oct 26, 2026.
- DailyMed: CIALIS (tadalafil) tablet, film coated, label revised 3/2026. Accessed Oct 26, 2026.
- DailyMed: APOKYN (apomorphine hydrochloride) injection, label revised 6/2022. Accessed Oct 26, 2026.
- FDA (Drugs@FDA): VIAGRA (sildenafil) prescribing information, NDA 020895. Accessed Oct 26, 2026.
- FDA (Drugs@FDA): CIALIS (tadalafil) prescribing information, NDA 021368. Accessed Oct 26, 2026.
- FDA: Compounding and the FDA, questions and answers. Accessed Oct 26, 2026.
- DailyMed: OZEMPIC (semaglutide) injection, Novo Nordisk, label revised 5/2026. Accessed Oct 26, 2026.
- DailyMed: WEGOVY (semaglutide) injection, Novo Nordisk, label revised 6/2026. Accessed Oct 26, 2026.
- DailyMed: MOUNJARO (tirzepatide) injection, Eli Lilly, label revised 8/2026. Accessed Oct 26, 2026.
- DailyMed: ZEPBOUND (tirzepatide) injection, Eli Lilly, label revised 8/2026. Accessed Oct 26, 2026.
- Able C, et al. Semaglutide for weight loss and erectile dysfunction: a TriNetX database study. Int J Impot Res. 2025;37(4):315-319. Accessed Oct 26, 2026.
- Cowart K, et al. Association of tirzepatide with erectile dysfunction in people with type 2 diabetes. J Diabetes Complications. 2025;39(10):109116. Accessed Oct 26, 2026.
- Esposito K, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978-84. Accessed Oct 26, 2026.
- NIDDK: symptoms and causes of ED. Accessed Oct 26, 2026.
- NIDDK: diagnosis of ED. Accessed Oct 26, 2026.
- FDA: concerns with unapproved GLP-1 drugs used for weight loss. Accessed Oct 26, 2026.
- Corona G, Sparano C, Romeo M, Rastrelli G, Vignozzi L, Maggi M. Emerging effects of GLP-1 receptor agonists and SGLT2 inhibitors on male sexual hormones and behaviors: systematic review and meta-analysis. Andrology. 2026;14(7):1988-2001. doi:10.1111/andr.70238. Accessed Oct 26, 2026.
- Lima JPC, Savergnini EL, Oliveira GRDS. Can GLP-1 receptor agonists be used in men with type 2 diabetes mellitus or obesity who complain of erectile dysfunction? A systematic review and meta-analysis (abstract 040). J Sex Med. 2026;23(Suppl 4). doi:10.1093/jsxmed/qdag118.035. Accessed Oct 26, 2026.
- Mendoxa ED care: product information. Accessed Oct 26, 2026.
- Mendoxa ED intake: plan prices (term_options). Accessed Oct 26, 2026.
About Mendoxa
Mendoxa (mendoxa.co) is a US telehealth brand. Independent licensed providers (licensed clinicians in the LocumTele network) review each online visit, and prescriptions are filled by Rush Pharmacy, a licensed US pharmacy. Available in 49 states (not California).
- Prescription required. A licensed clinician reviews every visit and can say no. A prescription is not automatic.
- A compounded medicine is not an FDA-approved finished product (FDA compounding Q&A).
- Plans: 1 month or 3 months, from $129. If prescribed · Cancel anytime · Available in 49 states (not California).
Compounded medication prescribed only if a licensed U.S. clinician decides it is appropriate. Not FDA-approved as a finished product. Not available in California. This site is not for emergencies. Call 911 if you need urgent care.